Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.

This study aims to compare the efficacy and safety of keverprazan-minocycline dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication, focusing on eradication rates, patient adherence, and the incidence of adverse drug reactions.

Inclusion Criteria: 1. Age 18-65 years; 2. Positive H. pylori status confirmed by 13C-urea breath test and no prior history of eradication therapy; 3. Voluntary participation and provision of written informed consent Exclusion Criteria: 1. Allergy to any study medication (e.g., minocycline, keverprazan, amoxicillin); 2. Confirmed active peptic ulcer disease; 3. Prior history of H. pylori eradication treatment; 4. Use of antibiotics or bismuth agents within 4 weeks before treatment initiation, or use of proton pump inhibitors within 2 weeks; 5. Current use of corticosteroids, nonsteroidal anti-inflammatory drugs, or anticoagulants; 6. History of esophageal or gastric surgery; 7. Pregnancy or lactation; 8. Severe comorbidities, including hepatic, cardiovascular, pulmonary, or renal disease; 9. Alcohol abuse; 10. Gastric mucosa-associated lymphoid tissue lymphoma, malignant tumors, peptic ulcer disease, or bronchial asthma; 11. Concurrent use of specific medications: atazanavir or rilpivirine, tricyclic antidepressants, levodopa, acetaminophen, guaifenesin/dextromethorphan, monoamine oxidase inhibitors, tramadol, or similar agents.